drugset

drugset / Trial / NCT07593027

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

NCT07593027 ↗

Phase 1/2 Recruiting 120 enrolled ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy

Timeline

Start: 2026-04-30
Primary completion: 2027-10-31
Completion: 2027-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	IMC-003	Unknown	—	—

Indications